The clinical trial of drug treatment designed by the French Abivax was called "miR-AGE".
Maybe it would have been better to find another name.
The biotech announced to end the clinical trial of its drug candidate against Covid-19, due to its "lack of effectiveness", in a press release published this Friday evening.
READ ALSO>
Why the hope of finding a miracle treatment is allowed
Called ABX464, this treatment had obtained the status of national research priority.
This single announcement was enough, at the end of December, to make the Abivax title fly off the Paris stock exchange by nearly 25%.
In May 2020, he received the green light from the French regulatory authorities (ANSM) to be tested against Covid-19, during his trial which included 1,034 patients.
It ended when 500 high-risk covid-19 patients against the disease had been recruited, the press release read.
It was conducted in a randomized, double-blind and placebo-controlled manner.
"Comparison of the data generated in patients treated with ABX464 versus the placebo group did not demonstrate any difference in the rate of progression to severe disease between the placebo group and the ABX464 group," the press release explains.
This drug was in fact aimed at preventing what doctors call "cytokine storm" and hyper-inflammation leading to acute respiratory distress syndrome (ARDS) and the death of patients with Covid-19.
The results were expected for the second trismester of 2021. They fell.
They are disappointing.
The adventure ends here, a little early.
